SCHEMBL2531168

SCHEMBL2531168

CCC(C)OC(=O)C(=CNc1ccnn1CC)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSK P43235 3/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
LMNA P02545 1/20 0.36
STAT1 P42224 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.34
DHODH Q02127 2/20 0.34
GAA P10253 2/20 0.34
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
MAPT P10636 3/20 0.33
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
KDM4E B2RXH2 1/20 0.33
NPY1R P25929 1/20 0.33
NPY2R P49146 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10961090 0.89 SMN1; SMN2 (0.34) CTSKNPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL10855247 0.88 CTSK (0.37) CTSKSMN1; SMN2NPSR1LMNASTAT1
SCHEMBL2535569 0.88 LMNA (0.38) CTSKRAB9ASMN1; SMN2NPSR1LMNA
SCHEMBL11791086 0.85 NPC1 (0.36) NPC1RAB9ANPSR1LMNASTAT1
SCHEMBL2794177 0.85 BTK (0.39) NPSR1L3MBTL1MEN1KMT2AMAPT
SCHEMBL3606132 0.84 SMN1; SMN2 (0.39) CTSKNPC1RAB9ASMN1; SMN2NPSR1
SCHEMBL11716091 0.81 GAA (0.46) SMN1; SMN2NPSR1LMNASTAT1L3MBTL1
SCHEMBL17963282 0.79 CTSK (0.39) CTSKRAB9AMEN1KMT2AMAPK1
SCHEMBL583550 0.78 DHODH (0.57) SMN1; SMN2NPSR1LMNASTAT1DHODH
SCHEMBL5046716 0.76 DHODH (0.58) RAB9ASMN1; SMN2NPSR1LMNADHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2560974-B1 PYRRAZOLOPYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2016-01-27 EP disclosed
US-8487102-B2 Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2013-07-16 US disclosed
EP-2560974-A1 PYRRAZOLOPYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2013-02-27 EP disclosed
WO-2011131571-A1 PYRRAZOLOPYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-10-27 WO disclosed
US-20110257402-A1 PYRRAZOLOPYRIDINE COMPOUNDS AS DUAL NK1/NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-10-20 US disclosed
US-4012373-A ANTIINFLAMMATORY, CNS DEPRESSANTS E. R. SQUIBB & SONS, INC. (US) 1977-03-15 US disclosed
US-3983128-A CNS DEPRESSANTS, ANTIINFLAMMATORY E. R. SQUIBB & SONS, INC. (US) 1976-09-28 US disclosed
US-3979399-A ATARACTIC, ANALGESIC, HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1976-09-07 US disclosed
US-3966746-A ATARACTIC, ANALGESIC, HYPOTENSIVE E. R. SQUIBB & SONS, INC. (US) 1976-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257402-A1 PYRRAZOLOPYRIDINE COMPOUNDS AS DUAL NK1/NK3 RECEPTOR ANTAGONISTS TACR2, GRIN3A, TACR1 CTSK 1531/4885NPC1 990/4885RAB9A 1448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.